ANI Pharmaceuticals made a recommended cash offer of about 5.3 billion kronor for Egetis Therapeutics, maker of Emcitate (tiratricol); the acceptance period is expected to open around November 20. Braveheart and Hengrui reported 52-week open-label data, with no comparison group, for oral BHB-1893 in adults with symptomatic obstructive HCM: 33 of 42 had a provoked gradient below 30 mmHg and 24 ended on the starting dose. Also: Amgen's real-world Repatha (evolocumab) vs. ezetimibe study; Lilly and Hims & Hers on Zepbound (tirzepatide) and Foundayo (orforglipron) self-pay access; Agios R&D role cuts; Moderna's norovirus cohort decision; and its Q3 revenue and raised outlook. This is the original Friday, November 6 edition, released late.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →